KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

Characterizing Cellular Expansion of Idecabtagene Vicleucel and Association with Clinical Efficacy and Safety in Patients with Triple-Class-Exposed Relapsed/Refractory Multiple Myeloma.

Fan Wu, Xirong Zheng, Joseph Burnett, Madhan Masilamani, Wanying Zhang, Xiaobo Zhong, Andrea Caia, Mark Cook, Julia Piasecki, Anna Kondic, Manisha Lamba, Jian Zhou

J Clin Pharmacol 65(11) 1568-1576

PMID40641008
PMCIDPMC12555096
DOI10.1002/jcph.70075
发表日期2025-07-11
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

Idecabtagene vicleucel (ide-cel, ABECMA) is an autologous, B-cell maturation antigen-directed, chimeric antigen receptor (CAR) T-cell therapy, which has demonstrated significantly improved progression-free survival (PFS) and overall response rate (ORR) in patients with triple-class-exposed relapsed/refractory multiple myeloma (TCE RRMM). Here, we characterize cellular expansion of ide-cel in vivo and further evaluate associations between cellular expansion and clinical efficacy and safety endpoints. The exposure parameters of ide-cel were evaluated through non-compartmental analysis methods using the time course data of CAR transgene copy numbers collected from the ide-cel arm of Study KarMMa-3 (NCT03651128). Multivariable regression analyses were conducted between the exposure parameters and clinical responses to characterize relationships between cellular expansion in vivo and clinical outcomes and to evaluate potential effects of covariates on the exposure-response (E-R) relationships. There appears to be lack of a strong association between actual ide-cel dose and cellular expansion at the dose range evaluated in Study KarMMa-3. The multivariable E-R regression models suggest positive relationships between cellular expansion and clinical efficacy and safety endpoints, with higher exposure associated with longer PFS, higher ORR, and higher rates of cytokine release syndrome requiring tocilizumab or corticosteroids. The current analyses do not identify any clinically relevant covariate effects on the E-R relationships. The positive exposure-response relationships were found to be overall similar between KarMMa-3 and a previous study KarMMa. The modeling analyses, paired with clinical data, support extending the dose range from previously approved 300-460 × 106 CAR+ T cells to 300-510 × 106 CAR+ T cells for TCE RRMM patients.

KM 提取结果

1 个 Figure · 2 个 KM 面板

进入结果中心
KM Figure2 个面板

Figure 2

Figure 2 Graphical evaluation of exposure–response relationships for efficacy by quartiles of exposure metrics. (a) Progress‐free suvival by AUC0‐28D; (b) Duration of response by AUC0‐28D; (c) Overall response rate (ORR) by Cmax/Tmax (i.e., expansion rate); (d) Minimal residual disease (MRD) negative status with complete response (CR) by Cmax/Tmax) (i.e., expansion rate).

A

Progression-Free Survival

Figure 2 · Panel A

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
B

Duration of Response

Figure 2 · Panel B

quality_warning 待 EXE 对齐 预期 4 条 已提取 2 条

Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

质量提示疑似重复轨迹:同一条 KM 曲线可能被重复识别疑似图例或人工水平线:轨迹出现不合理的共同平台曲线缺失:预期 4 条,实际恢复 2 条疑似重复轨迹:同一条 KM 曲线可能被重复识别
查看结果
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Predicted AUC0‐28D versus actual dose for the model fitted by KarMMa‐3 data. Open circles represent observed data. Solid line represents predicted dose–AUC0‐28D relationship profile for the reference patients and the shaded area represents the 95% confidence interval.
非 KM Figure
Figure 3Figure 3 Graphical evaluation of E‐R relationship for safety events versus expansion rate. (a) Rate of cytokine release syndrome requiring tocilizumab/siltuximab treatment (tCRS); (b) Rate of CRS requiring corticosteroid treatment (sCRS); (c) Rate of CRS at all grades; (d) Rate of CSR at Grade 3 or above; (e) Investigator‐identified neurotoxicity at Grade 2 or above; (f) Cytopenia Grade 3 or above without showing recovery to less than Grade 2 within Month 1. Note: Expansion rate is defined as Cmax/Tmax.
非 KM Figure